Mesoblast Ltd has released a press release.
MSB Strengthens US Patent Portfolio For Rheumatic Diseases
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- Mesoblast P2 Results Show Dose-Related Improvements In RA
- MSB Back Pain Results Presented, Receive Best Science Award
- Update on Heart Failure Trial and Funding of Operations
- Update on Global Heart Failure Program
- Suspension from Official Quotation
Later from Mesoblast
- Preliminary Final Report (Including Appendix 4E)
- Mesoblast Phase 2 Diabetic Kidney Disease Results Published
- MSB Japan Strategy Highlighted At Business Council Meeting
- Successful Interim Futility Analysis In P3 Trial for GVHD
- First Quarter Results On Form 6K
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast